OTC Hearing Aid Market Surpasses $1.2B in Annual Sales Two Years After FDA Rule Change

The numbers behind the growth

The U.S. OTC hearing aid market reached an estimated $1.24 billion in annual sales in 2025, according to new industry analysis — representing a compound annual growth rate of approximately 34% since the FDA's over-the-counter hearing aid rule took effect in October 2022. Pre-rule projections from most analysts had forecast the market reaching this milestone by 2027 or 2028.

Unit sales tell an even more striking story. Approximately 2.8 million OTC hearing aids were sold in the United States in 2025, compared to an estimated 4.1 million prescription hearing aids — a ratio that would have been unthinkable before the rule change, when the prescription market had a near-total monopoly on hearing amplification devices.

Who is buying OTC hearing aids

Consumer surveys conducted alongside the market analysis reveal a profile that differs meaningfully from the traditional prescription hearing aid buyer:

Younger first-time buyers: The average age of an OTC hearing aid purchaser is 58, compared to 69 for a first-time prescription hearing aid user. The lower price point and lack of required clinical visits appear to be drawing in people who would otherwise have delayed treatment.

Mild-to-moderate loss: Consistent with the FDA's intended target population, the majority of OTC buyers report mild or moderate hearing difficulty. However, surveys suggest that a meaningful minority — estimated at 15–20% — have hearing loss that would benefit more from a prescription device.

Price-driven decisions: Cost remains the dominant purchase driver. The average OTC hearing aid sells for $400–$1,500 per pair, compared to $4,000–$7,000 for prescription devices. For the estimated 28 million Americans with untreated hearing loss who cite cost as the primary barrier, OTC devices represent a meaningful entry point.

Tech-comfortable demographics: OTC buyers skew toward consumers comfortable with smartphone apps and self-fitting technology — a profile that aligns with the device category's reliance on app-based customization.

The competitive landscape is shifting rapidly

Consumer electronics brands leading volume

Sony, Jabra, and Bose collectively account for an estimated 45% of OTC unit sales, leveraging their existing brand recognition, retail distribution networks, and consumer electronics expertise. These brands have invested heavily in app-based fitting and Bluetooth connectivity — features that resonate with their existing customer base.

Prescription brands entering the OTC space

The major prescription hearing aid manufacturers — Phonak, Oticon, Signia, ReSound, Starkey, and Widex — have all either launched or announced OTC or direct-to-consumer product lines. Their strategy differs from the consumer electronics approach: rather than competing on price, they are positioning their OTC offerings as premium devices with clinical-grade sound processing at a lower price point than their prescription lines.

This creates a new middle tier in the market — devices priced at $1,500–$2,500 per pair that offer more sophisticated signal processing than entry-level OTC devices but do not require a clinical fitting.

Telehealth integration

Several brands are blurring the line between OTC and prescription by offering remote audiologist consultations as an add-on service. This hybrid model — sometimes called "assisted OTC" — allows consumers to purchase a device directly while still accessing professional guidance for fitting and adjustment. Eargo and Jabra Enhance have been the most aggressive in developing this model.

What the growth means for consumers

The rapid market expansion has several practical implications for people shopping for hearing aids today:

More choice, more complexity: The proliferation of OTC devices has made comparison shopping significantly more difficult. Feature sets, fitting approaches, and sound processing quality vary enormously across price points and brands.

Return policies matter more: Because OTC devices cannot be professionally fitted before purchase, return policies are a critical consumer protection. Most reputable OTC brands now offer 30–45 day trial periods, but terms vary significantly.

The prescription market is responding on price: Increased OTC competition has put downward pressure on prescription hearing aid prices. Several major manufacturers have introduced entry-level prescription lines priced below $3,000 per pair — a significant shift from the historical norm.

Insurance coverage is evolving: As OTC devices gain market share, some insurance plans are beginning to include OTC hearing aid benefits. Medicare Advantage plans in particular have been expanding hearing aid coverage, though benefit structures vary widely.

The unmet need remains enormous

Despite the market's rapid growth, the fundamental problem — widespread untreated hearing loss — remains largely unaddressed. The National Institute on Deafness and Other Communication Disorders estimates that only about 1 in 5 Americans who could benefit from a hearing aid actually uses one.

The OTC rule change was designed to address this treatment gap by removing cost and access barriers. The market data suggests it is working — but slowly. At current growth rates, it will take years before OTC devices meaningfully close the gap between the number of people with treatable hearing loss and the number receiving treatment.

Audiologists and hearing health advocates note that market growth alone is not sufficient. Consumer education — helping people recognize the signs of hearing loss, understand their options, and make informed decisions between OTC and prescription devices — remains a critical piece of the puzzle.